FDA refuses to consider Moderna flu shot in move experts claim is part of ‘anti-vaccine agenda’

AI Summary
The US Food and Drug Administration (FDA) has refused to consider Moderna's application for a new flu vaccine based on messenger RNA (mRNA) technology. The decision was made after a senior FDA official described the clinical trial as a "brazen failure" due to design issues, including a control group that did not receive the best-available standard of care in the US at the time of the study. Experts claim this is part of an "anti-vaccine agenda", citing concerns over the rejection of mRNA vaccines and other conventional science. The decision has been criticized by experts, who argue that the FDA's communication on the issue raises alarm and appears to be politically motivated. Moderna says the FDA frequently weighed in on its application during development. The rejection is seen as having a chilling effect on vaccine development.
Key Entities & Roles
Keywords
Sentiment Analysis
Source Transparency
This article was automatically classified using rule-based analysis. The political bias score ranges from -1 (far left) to +1 (far right).
Topic Connections
Explore how the topics in this article connect to other news stories
Find Similar Articles
AI-PoweredDiscover articles with similar content using semantic similarity analysis.